S.Biomedics Co., Ltd. (KOSDAQ:304360)

South Korea flag South Korea · Delayed Price · Currency is KRW
34,200
+1,650 (5.07%)
At close: Dec 5, 2025
80.95%
Market Cap 408.51B
Revenue (ttm) 16.96B
Net Income (ttm) -9.58B
Shares Out 11.94M
EPS (ttm) -810.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 372,161
Average Volume 180,118
Open 34,450
Previous Close 32,550
Day's Range 32,850 - 36,600
52-Week Range 16,130 - 36,600
Beta 1.60
RSI 75.22
Earnings Date Nov 13, 2025

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2005
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 304360
Full Company Profile

Financial Performance

In 2024, S.Biomedics's revenue was 13.73 billion, an increase of 4.77% compared to the previous year's 13.11 billion. Losses were -6.69 billion, -35.17% less than in 2023.

Financial Statements

News

There is no news available yet.